Managing Selected CTEP Software tools

癌症治疗评估计划(CTEP)的使命是通过找到更好的治疗、控制和治愈癌症的方法来改善癌症患者的生活。CTEP通过资助一项广泛的全国癌症研究计划和赞助临床试验来评估新的抗癌药物，特别是强调阐明药物作用的分子靶标和机制的转译研究，来完成这一使命。 CTEP使用科学过程来完成其任务： *通过确定新的评估药物和确定可用于临床的肿瘤的生物学特征，确定有希望的基础科学发现并将其转化为临床研究。 *识别具有独特分子靶点、作用机制或特性的新型抗癌药物，并将其引入临床试验，根据科学标准和治疗需要确定药物的优先顺序。 *在临床试验中系统地评估新的抗癌药物的抗肿瘤活性。 *在假说驱动的临床试验中，将有希望的新癌症治疗方法与最好的可用治疗方法进行严格比较，以可靠地确定针对特定类型癌症的优越治疗方法 CTEP试图在研究界建立广泛的合作，并与制药/生物技术行业广泛合作，有效地开发新的癌症治疗方法。CTEP还寻求让外部专家和患者或他们的倡导者参与制定研究优先事项。在为NCI赞助的临床研究的选择中，CTEP试图填补国家癌症研究工作中的关键空白，并避免正在进行的私营部门工作的重复。在进一步控制癌症的努力中，积极的新抗癌剂被尽可能迅速和广泛地提供给患者。

The mission of the Cancer Therapy Evaluation Program (CTEP) is to improve the lives of cancer patients by finding better ways to treat, control and cure cancer. CTEP accomplishes this mission by funding an extensive national program of cancer research and by sponsoring clinical trials to evaluate new anti-cancer agents, with a particular emphasis on translational research to elucidate molecular targets and mechanisms of drug effects. CTEP uses a scientific process to accomplish its mission: * promising basic science findings are identified and translated into clinical research, both by identifying new agents for evaluation and by identifying biologic characteristics of tumors that may be clinically exploited. * novel anti-cancer agents with distinctive molecular targets, mechanisms of action, or properties are identified and introduced into clinical trials, with prioritization of agents based on scientific criteria and therapeutic needs. * the anti-tumor activity of new anti-cancer agents is systematically evaluated in clinical trials. * promising new cancer treatments are rigorously compared to best available treatments in hypothesis-driven clinical trials to reliably define superior treatments for specific types of cancer CTEP attempts to forge broad collaborations within the research community and works extensively with the pharmaceutical/biotechnology industry to effectively develop new cancer treatments. CTEP also seeks to involve outside experts and patients or their advocates in the formulation of research priorities. In the selection of clinical research for NCI sponsorship, CTEP attempts to fill critical gaps in the national cancer research effort and to avoid duplication of ongoing private sector efforts. In further efforts to control cancer, active new anticancer agents are made available as rapidly and widely as possible for patients.